Clinical Edge Journal Scan

Family history of breast cancer in first-degree relatives may increase risk for certain cancers in men


 

Key clinical point: Men with a family history of breast cancer (FHBC) in either mother or sister are at a higher risk of developing pancreatic, thyroid, prostate, and breast cancers than men without FHBC and, therefore, may need more vigilant cancer surveillance.

Major finding: An FHBC in both mother and sister was associated with an increased overall cancer risk (hazard ratio [HR] 1.69; 95% CI 1.11-2.57), whereas an FHBC in either mother or sister significantly increased the risk of developing pancreatic cancer (HR 1.35; 95% CI 1.07-1.70), breast cancer (HR 3.03; 95% CI 1.13-8.17), thyroid cancer (HR 1.33; 95% CI 1.12-1.56), and prostate cancer (HR 1.28; 95% CI 1.13-1.44).

Study details: Findings are from a population-based study including 2,734,889 men aged ≥40 years, of which 69,124 men had a FHBC in their mother or sister and 276,496 men had no history of cancer in any of their first-degree relatives.

Disclosures: This study was supported by a National Research Foundation of Korea grant. The authors declared no conflicts of interest.

Source: Song H, Jung YS, et al. Increased risk of pancreatic, thyroid, prostate and breast cancers in men with a family history of breast cancer: A population-based study. Int J Cancer. 2023 (May 29). doi: 10.1002/ijc.34573

Recommended Reading

In TNBC, repeated biopsies may reveal emergent HER2-low expression
Breast Cancer ICYMI
New study backs up capecitabine dosing practice in metastatic BC
Breast Cancer ICYMI
ACS officer provides ASCO highlights: Targeting hidden cancer, AI in oncology
Breast Cancer ICYMI
HR+/HER2− BC: Dalpiciclib plus letrozole or anastrozole shows promise in phase 3
Breast Cancer ICYMI
HR+/HER2− BC patients progressing on initial ET can switch ET while continuing CDK4/6i
Breast Cancer ICYMI
Node-positive early BC: Targeted axillary dissection without axillary lymph node dissection oncologically safe
Breast Cancer ICYMI
Early-stage BC: Meta-analysis shows better outcomes with partial vs whole breast irradiation
Breast Cancer ICYMI
CDK4/6 inhibitors+ET improves survival in elderly patients with ER+ advanced BC
Breast Cancer ICYMI
Extended letrozole therapy benefits early-stage HR+ BC patients for over 10 years
Breast Cancer ICYMI
Low ERBB2 expression does not worsen prognosis in patients receiving endocrine plus targeted therapy in HR+ BC
Breast Cancer ICYMI